UTHR icon

United Therapeutics

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 43.2%
Negative

Neutral
Investors Business Daily
8 days ago
United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base
The Big Cap 20 pick to watch is United Therapeutics stock, which is up 72% in the last few months.
United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base
Positive
Zacks Investment Research
9 days ago
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
Neutral
Seeking Alpha
11 days ago
United Therapeutics Corporation (UTHR) Presents at Jefferies London Healthcare Conference 2025 Transcript
United Therapeutics Corporation ( UTHR ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Harrison Silvers - Manager of Investor Relations James Edgemond - CFO & Treasurer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Welcome, everyone, to Jefferies London Healthcare Conference 2025. My name is Roger Song, one of the senior analysts cover SMid-cap biotech in the U.S. It is my pleasure to have the fireside chat with our next company, United Therapeutics, James and Harry.
United Therapeutics Corporation (UTHR) Presents at Jefferies London Healthcare Conference 2025 Transcript
Positive
Zacks Investment Research
17 days ago
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
Neutral
Seeking Alpha
19 days ago
United Therapeutics Corporation (UTHR) Presents at UBS Global Healthcare Conference 2025 Transcript
United Therapeutics Corporation ( UTHR ) UBS Global Healthcare Conference 2025 November 10, 2025 9:30 AM EST Company Participants Patrick Poisson - Executive VP of Technical Operations Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Terence Flynn - Morgan Stanley, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. Welcome to UBS Healthcare Conference.
United Therapeutics Corporation (UTHR) Presents at UBS Global Healthcare Conference 2025 Transcript
Positive
Zacks Investment Research
24 days ago
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Positive
Zacks Investment Research
25 days ago
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Neutral
Business Wire
26 days ago
United Therapeutics Corporation to Present at Upcoming Investor Conferences
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming investor conferences. Patrick Poisson, Executive Vice President, Strategic Development, will present at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 10, 2025, from 9:30 a.m. to 10:0.
United Therapeutics Corporation to Present at Upcoming Investor Conferences
Neutral
Business Wire
27 days ago
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its EXPAND study of the UKidney™ in patients with end-stage renal disease (ESRD). The successful transplant operation was performed at NYU Langone Health. United Therapeutics' UKidney is an investigational xenokidney from a pig with 10 gene edits. Six human genes are added to the pig genome to facilitate immunological accept.
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
Positive
Zacks Investment Research
1 month ago
MKKGY vs. UTHR: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?
MKKGY vs. UTHR: Which Stock Is the Better Value Option?